Chemical pleurodesis using povidon-iodine for chylothorax treatment in newborns

Abstract

Introduction. Chylothorax is a rare condition that results from abnormal accumulation of lymphatic fluid in the chest and one of the most common causes of pleural effusion in newborns. The aim of our study is to present our own experience of chemical pleurodesis using povidone-iodine in newborns with chylothorax.

Materials and methods. In the present study, we studied data from 10 patients with chylothorax who, over the past years, starting in 2016, underwent chemical pleurodesis using the drug povidone-iodine. Congenital accumulation of lymph in the pleural cavity was recorded in 2 patients, acquired — in 8 patients. The indications for this procedure were the absence of response to total parenteral nutrition for at least 10 days and the appointment of octreotide at the maximum dosage. Pleurodesis consisted in the introduction into the pleural cavity of a 4% solution of povidone-iodine with a calculated dose of 1 ml/kg. The povidone-iodine solution was kept inside the pleural cavity for the next 4 hours.

Results. Chemical pleurodesis was successfully applied in all 10 patients. In 8 patients, a single prescription of the drug was sufficient, and in 2 remaining patients, the pleurodesis session was repeated. After the procedure of chemical pleurodesis, 2 patients developed respiratory distress syndrome caused by massive atelectasis of the homolateral lung, which was confirmed by X-ray examination. These patients required mechanical ventilation for 24 and 48 hours. The average time for the disappearance of chylothorax was 4 days. In the long-term follow-up, 1 patient died from progressive deterioration of pulmonary function against the background of lung hypoplasia.

Conclusions. Our data demonstrate that povidone iodine pleurodesis is a effective treatment for chylothorax in newborns.

Keywords

chylothorax / chemical pleurodesis / povidone-iodine / newborns

References

[1] Scottoni F, Fusaro F, Conforti A, et al. Pleurodesis with povidone-iodine for refractory chylothorax in newborns: Personal experience and literature review. J Pediatr Surg. 2015;50(10):1722–1725. doi: 10.1016/j.jpedsurg.2015.03.069

[2] Christofe NM, Pessotti CFX, Paiva L, et al. Incidence and Treatment of Chylothorax in Children Undergoing Corrective Surgery for Congenital Heart Diseases. Braz J Cardiovasc Surg. 2017;32(5):390–393. doi: 10.21470/1678-9741-2017-0011

[3] Dorsi M, Giuseppi A, Lesage F, et al. Prenatal factors associated with neonatal survival of infants with congenital chylothorax. J Perinatol. 2018;38(1):31–34. doi: 10.1038/jp.2017.150.

[4] Concheiro-Guisan A, Alonso-Clemente S, Suarez-Albo M, et al. The Practicality of Feeding Defatted Human Milk in the Treatment of Congenital Chylothorax. Breastfeed Med. 2019;14(9):648–653. doi: 10.1089/bfm.2019.0100

[5] White MK, Bhat R, Greenough A. Neonatal Chylothoraces: A 10-Year Experience in a Tertiary Neonatal Referral Centre. Case Rep Pediatr. 2019;2019:3903598. doi: 10.1155/2019/3903598

[6] Long WG, Cai B, Deng JM, et al. Chemical pleurodesis and somatostatin in treating spontaneous chylothorax in pediatric patients: a retrospective analysis and review of the literature. Transl Pediatr. 2020;9(4):551–560. doi: 10.21037/tp-20-199

[7] Le Nué R, Molinaro F, Gomes-Ferreira C, et al. Surgical management of congenital chylothorax in children. Eur J Pediatr Surg. 2010;20(5):307–311. doi: 0.1055/s-0030-1254164

[8] Moreira-Pinto J, Rocha P, Osório A, et al. Octreotide in the treatment of neonatal postoperative chylothorax: report of three cases and literature review. Pediatr Surg Int. 2011;27(8):805–809. doi: 10.1007/s00383-010-2730-2

[9] Soto-Martinez M, Massie J. Chylothorax: diagnosis and management in children. Paediatr Respir Rev. 2009;10(4):199–207. doi: 10.1016/j.prrv.2009.06.008

[10] Azizkhan RG, Canfield J, Alford BA, et al. Pleuroperitoneal shunts in the management of neonatal chylothorax. J Pediatr Surg. 1983;18(6):842–850. doi: 10.1016/S0022-3468(83)80034-7

[11] Brissaud O, Desfrere L, Mohsen R, et al. Congenital idiopathic chylothorax in neonates: chemical pleurodesis with povidone-iodine (Betadine). Arch Dis Child Fetal Neonatal Ed. 2003;88(6):F531–533. doi: 10.1136/fn.88.6.F531

[12] Beer H, Mol M, Janssen J. Chylothorax. Neth J Med. 2000;56:25–31. doi: 10.1016/S0300-2977(99)00114-X

[13] Kim JE, Lee C, Park KI, et al. Successful pleurodesis with OK-432 in preterm infants with persistent pleural effusion. Korean J Pediatr. 201;55:177–180. doi: 10.3345/kjp.2012.55.5.177

[14] Cho H, Na K, Kim D, et al. Chemical pleurodesis using a Viscum album extract in infants with congenital chylothorax. Eur J Pediatr. 2014;173:823–826. doi: 10.1007/s00431-014-2283-9

[15] Mitanchez D, Walter-Nicolet E, Salomon R, et al. Congenital chylothorax: what is the best strategy? Arch Dis Child Fetal Neonatal Ed. 2006;91:153–154. doi: 10.1136/adc.2004.069690

[16] Roehr CC, Jung A, Proquitté H, et al. Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review. Intensive Care Med. 2006;32(5):650–657. doi: 10.1007/s00134-006-0114-9

[17] Büttiker V, Fanconi S, Burger R.Chylothorax in children: guidelines for diagnosis and management. Chest. 1999;116(3):682–687. doi: 10.1378/chest.116.3.682

[18] Rimensberger PC, Müller-Schenker B, Kalangos A, et al. Treatment of a persistent postoperative chylothorax with somatostatin. Ann Thorac Surg. 1998;66:253–254. doi: 10.1016/S0003-4975(98)00361-0

[19] Das A, Shah PS. Octreotide for the treatment of chylothorax in neonates. Cochrane Database Syst Rev. 2010;08:CD006388. doi: 10.1002/14651858.CD006388.pub2

[20] Bellini C, Cabano R, De Angelis LC, et al. Octreotide for congenital and acquired chylothorax in newborns: A systematic review. J Paediatr Child Health. 2018;54:840–847. doi: 10.1111/jpc.13889

[21] Azam MN, Majhi SK, Mishra BN, et al. Bilateral spontaneous chylothorax in a newborn and response to octreotide therapy. Int J Contemp Pediatr. 2017;4:658–660. Doi: 10.18203/2349-3291.ijcp20170727

[22] Church JT, Antunez AG, Dean A, et al. Evidence-based management of chylothorax in infants. J Pediatr Surg. 2017;52:907–912. doi: 10.1016/j.jpedsurg.2017.03.010

[23] Çakır U, Kahvecioğlu D, Yıldız D, et al. Report of a case of neonatal chylothorax that responded to long-term octreotide treatment, and review of the literature. Turk J Pediatr. 2015;57:195–197.

[24] Saito M, Kamoda T, Kajikawa D, et al. High Dose Octreotide for the Treatment of Chylothorax in Three Neonates. J Neonatal Biol. 2016;5:218. doi: 10.4172/2167-0897.1000218

[25] Dehghan K. Idiopathic Chylothorax in a Term Neonate and Successful Treatment with Octreotide and Medium Chain Triglyceride — Enriched Formula: A Case Report. Int J Pediatr. 2019;7:9535–9540.

[26] Cleveland K, Zook D, Harvey K, et al. Massive chylothorax in small babies. J Pediatr Surg. 2009;44(3):546–550. doi: 10.1016/j.jpedsurg.2008.08.008

[27] Beghetti M, La Scala G, Belli D, et al. Etiology and management of pediatric chylothorax. J Pediatr. 2000;136(5):653–658. doi: 10.1067/mpd.2000.104287

[28] Wolff AB, Silen ML, Kokoska ER, et al. Treatment of refractory chylothorax with externalized pleuroperitoneal shunts in children. Ann Thorac Surg. 1999;68(3):1053–1057. doi: 10.1016/S0003-4975(99)00880-2

[29] Mattei P, editor. Fundamentals of Pediatric Surgery. New York: Springer; 2011. 311 p. doi: 10.1007/978-1-4419-6643-8

[30] Разумовский, А.Ю., Степанов Э.А. Хилоторакс в детском возрасте. М.: ГЭОТАР-Медиа, 2011. [Razumovskij AJ, Stepanov JA. Hilotoraks v detskom vozraste. Moscow: GEOTAR-Media, 2011. (In Russ.)]

[31] Nath DS, Savla J, Khemani RG,et al. Thoracic duct ligation for persistent chylothorax after pediatric cardiothoracic surgery. Ann Thorac Surg. 2009;88(1):246–251. doi: 10.1016/j.athoracsur.2009.03.083

[32] Pego-Fernandes PM, Nascimbem MB, Ranzani OT, et al. Video-assisted thoracoscopy as an option in the surgical treatment of chylothorax after cardiac surgery in children. J Bras Pneumol. 2011;37(1):28–35. doi: 10.1590/S1806-37132011000100006

[33] Echavarría A, Pinzón V, Barés JP, et al. Intracavitary treatment of malignant pleural effusion with iodine-povidone. Rev Med Panama. 1991;16(1):69–74.

[34] Guo Y, Tang K, Bilaceroglu S, et al. Iodopovidon is as effective as doxycycline in producing pleurodesis in rabbits. Respirology. 2010;15(1):119–121. doi: 10.1111/j.1440-1843.2009.01671.x

[35] Cohan RH, Saeed M, Schwab SJ, et al. Povidone-iodine sclerosis of pelvic lymphoceles: a prospective study. Urol Radiol. 1988;10(4):203–206. doi: 10.1111/j.1440-1843.2009.01671.x

[36] Olivares-Torres CA, Laniado-Laborín R, Chávez-García C, et al. Iodopovidone pleurodesis for recurrent pleural effusions. Chest. 2002;122(2):581–583. doi: 10.1378/chest.122.2.581

[37] Agarwal R, Khan A, Aggarwal AN, et al. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis. Indian J Med Res. 2012;135:297–304.

[38] Murki S, Faheemuddin M, Gaddam P. Congenital chylothorax — successful management with chemical pleurodesis. Indian J Pediatr. 2010;77(3):332–334. doi: 10.1007/s12098-010-0022-4.

[39] Resch B, Freidl T, Reiterer F. Povidone-iodine pleurodesis for congenital chylothorax of the newborn. Arch Dis Child Fetal Neonatal Ed. 2016;101:87–88. doi: 10.1136/archdischild-2015-309184

[40] Borcyk K, Kamil A, Hagerty K, et al. Successful management of extremely high-output refractory congenital chylothorax with chemical pleurodesis using 4% povidone-iodine and propranolol: a case report. Clin Case Rep. 2018;6(4):702–708. doi: 10.1002/ccr3.1449

RIGHTS & PERMISSIONS

Kozlov Y.A., Rasputin A.A., Kovalkov K.A., Poloyan S.S., Baradieva P.Z., Zvonkov D.A., Ochirov C.B., Cheremnov V.S., Kapuller V.M.